Author Archives: admin


Stem Cell Clinic > Articles by: admin

Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020

By Global News Feed

ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its third quarter 2020 financial results will be reported on Tuesday, November 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

More here:
Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020

Chiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness Day

By Global News Feed

NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to people with acromegaly and the patient advocacy groups in their ongoing efforts to increase awareness of acromegaly and support the unique needs of people living with acromegaly.

Original post:
Chiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness Day

Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020

By Global News Feed

CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2020 financial results and provide a corporate update before market open on Friday, November 6, 2020. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET.

Follow this link:
Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020

BioVie Interview to Air on Bloomberg International on the RedChip Money Report

By Global News Feed

SANTA MONICA, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will air on The RedChip Money Report television program this Sunday November 1st. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

More here:
BioVie Interview to Air on Bloomberg International on the RedChip Money Report

Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B

By Global News Feed

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has dosed its first subject in a first-in-human Phase 1a/b clinical trial, ALG-000184-201 (NCT04536337). The study will evaluate ALG-000184, a small molecule class II capsid assembly modulator (CAM) that targets hepatitis B virus (HBV) capsid assembly as well as the establishment of covalently closed circular DNA (cccDNA).

See the original post:
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B

→←